PILL.CN - Canntab Therapeutics Limited

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
1.09
-0.06 (-5.22%)
At close: 3:52PM EST
Stock chart is not supported by your current browser
Previous Close1.15
Open0.00
Bid1.07 x 0
Ask1.09 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume173,910
Market Cap27.56M
Beta (3Y Monthly)0.94
PE Ratio (TTM)N/A
EPS (TTM)-0.12
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2016-03-08
1y Target EstN/A
  • GlobeNewswire7 days ago

    Canntab Announces Correction to Press Release 

    NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. TORONTO, Nov. 14, 2018 -- Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or.

  • GlobeNewswire7 days ago

    Canntab Corporate Update

    Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”) is a company with a clear vision of becoming the leader in solid oral dosage formulation of cannabis.  Their unique products offer advantages to the medical community, patients, adult use consumers and governments.  Canntab is pleased to provide this corporate update to its shareholders. A strong intellectual property portfolio with 13 patents pending in the United States and Canada pertaining to the formulation of tablets including instant release, extended release, flash melt and bi-layered. An application to become a Licensed Producer (Non Grower) under the Access to Cannabis for Medical Purposes Regulations and has confirmation from Health Canada that its application had been received.

  • GlobeNewswire21 days ago

    Canntab to Enter Medicinal Cannabis Market in Mexico

    Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”) today announced the signing of a non-binding Letter of Intent (the “LOI”) with Labsco Promedic SA de CV of Monterrey, Mexico (“Labsco”) for the establishment of a joint venture relationship for the sales & distribution of Canntab products in Mexico (the “Territory”) on an exclusive basis. Following the LOI, the parties will work together to establish and complete a formal joint venture relationship for an initial period of five years.

  • Newsfilelast month

    InvestmentPitch Media Video Discusses Canntab Therapeutics and its Application to Become a Licensed Producer Under ACMPR with Health Canada - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - October 22, 2018) -  Canntab Therapeutics (CSE: PILL) (FSE: TBF1), a Canadian cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has filed an application to become a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations with Health Canada. The License, if granted by Health Canada, would allow the company to process cannabis products at its current ...

  • GlobeNewswirelast month

    Canntab Files Application to Become Licensed Producer

    Canntab Therapeutics Limited (CSE:PILL) (“Canntab” or the “Company”), a leader in the development of precision oral dose cannabis tablets and capsules, is pleased to announce that it has filed an application to become a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (the “License”), and that it received confirmation from Health Canada that its application had been received. The License, if granted by Health Canada, would allow the Company to process cannabis products at its current production facility in Markham, Ontario with minimal additional capital expenditures as compared to a new purpose-built facility. “We are excited to announce, as we enter into a new era of legalization, that Canntab has submitted its application to Health Canada to become a Licensed Producer.

  • Newsfilelast month

    Canntab Files Application to Become Licensed Producer

    Toronto, Ontario--(Newsfile Corp. - October 18, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") a leader in the development of precision oral dose cannabis tablets and capsules, is pleased to announce that it has filed an application to become a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (the "License"), and that it received confirmation from Health Canada that its application had been received. The License, ...

  • Newsfile2 months ago

    Canntab Therapeutics, Extended Release Cannabis Tablets, CEO Clip Video

    Vancouver, British Columbia--(Newsfile Corp. - October 4, 2018) - Jeff Renwick, CEO of Canntab Therapeutics speaks about their proprietary solid cannabis delivery system technology. If you cannot view the video above, please visit:https://www.b-tv.com/canntab-therapeutics-ceo-clip-90sec/Canntab Therapeutics is being featured on BNN Bloomberg on Oct. 13 — Oct. 14, 2018 Monday through Friday, throughout the day and evenings.Canntab Therapeutics (CSE: PILL)canntab.caAbout CEO Clips:CEO Clips is the largest library of publicly traded company CEO videos in ...

  • Newsfile2 months ago

    InvestmentPitch Media Video Discusses Canntab Therapeutics LOI With NewCanna of Colombia to Distribute Canntab Products in Select Countries - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - October 4, 2018) -  Canntab Therapeutics (CSE: PILL) (FSE: TBF1), a Canadian cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has Signed a non-binding Letter of Intent with NewCanna S.A.S. of Bogota, Colombia, The LOI establishes a significant bi-lateral relationship granting NewCanna the right to sell and distribute certain Canntab exclusive proprietary products, and the right to utilize Canntab's ...

  • Newsfile2 months ago

    Canntab Enters LOI for Bi-Lateral Sales & Distribution and Cannabis Oil Supply

    Toronto, Ontario--(Newsfile Corp. - October 1, 2018) - Canntab Therapeutics Limited (CSE: PILL) (FSE: TBF1) ("Canntab" or the "Company"), today announced the completion of a non-binding Letter of Intent (the "LOI") with NewCanna S.A.S of Bogota, Colombia ("NewCanna") for the establishment of a significant bi-lateral relationship for the sale & distribution of Canntab's products. The territory applicable to the agreement is the countries of Colombia, Chile, Paraguay and Spain, (collectively, the "Territory"). The ...

  • Newsfile2 months ago

    FSD Pharma Receives First Delivery of Canntab Equipment with a Capacity to Manufacture Approx. 1,500,000 Tablets per Day

    Toronto, Ontario--(Newsfile Corp. - September 25, 2018) - FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FSE: 0K9) ("FSD Pharma" or the "Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that the Company has received its first delivery of manufacturing equipment at its Cobourg plant from Canntab Therapeutics Limited (CSE: PILL) ("Canntab"), a leader in ...

  • Newsfile2 months ago

    Canntab Added to CSE Composite Index

    Toronto, Ontario--(Newsfile Corp. - September 24, 2018) - Canntab Therapeutics Limited (CSE: PILL) (FSE: TBF1) ("Canntab" or the "Company"), is pleased to inform investors that effective September 21, 2018 the Company has been added to the Composite Index of the Canadian Securities Exchange as part of the CSE's quarterly rebalancing.Based on the September 21 closing price of PILL, the Company's market capitalization is above the average market cap of the Index component companies and ...

  • Newsfile2 months ago

    Canntab Sets New All-Time High Trading Prices and Volume

    Toronto, Ontario--(Newsfile Corp. - September 20, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company"), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that the Company's common shares ("Common Shares") yesterday reached new all-time daily high and closing prices of $1.74 and $1.41, respectively, on the Canadian Securities Exchange (the "CSE"). These numbers exceed the Company's previous all-time highs by 39.2% and 15.6%, ...

  • Newsfile2 months ago

    Canntab Exceeds All-Time High Trading Prices and Grants Options

    Toronto, Ontario--(Newsfile Corp. - September 19, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company"), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that the Company's common shares ("Common Shares") yesterday reached new all-time daily high and closing prices of $1.25 and $1.22, respectively, on the Canadian Securities Exchange (the "CSE"). This constitutes a 25% and 22% premium on the price of the ...

  • Newsfile2 months ago

    Canntab Signs Collaboration and Profit Sharing Agreement with FSD Pharma for Production and Market of Oral Dose Delivery Platforms

    Toronto, Ontario--(Newsfile Corp. - September 18, 2018) - Canntab Therapeutics Limited (CSE: PILL) (the "Company" or "Canntab") is pleased to announce that it has signed a definitive collaboration and profit sharing agreement (the "Agreement) (OTC Pink: FSDDF) (FRA: 0K9) ("FSD Pharma"), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, effective September 17, 2018. Under the terms of the Agreement, FSD Pharma ...

  • Newsfile2 months ago

    Canntab and Emblem Announce Positive Results on Testing: Proceeding to Clinical Trials

    Toronto, Ontario--(Newsfile Corp. - September 18, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company"), today announced the achievement of a milestone with regards to the development of a patent-pending oral extended release formulation for cannabinoids in collaboration with Emblem Corp. (TSXV: EMC) (OTCQX: EMMBF), a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") through its wholly-owned subsidiary Emblem Cannabis Corporation (collectively, "Emblem"). Dissolution testing conducted by ...

  • Newsfile2 months ago

    Canntab Therapeutics Launches Capital Markets Communications Strategy

    Toronto, Ontario--(Newsfile Corp. - September 11, 2018) - Canntab Therapeutics Limited (CSE: PILL) (the "Company" or "Canntab") is pleased to announce that, effective today, the Company will be increasing its level of engagement with shareholders and with potential retail and institutional investors. Accordingly, it has retained the services of Mackie Research Capital Corporation ("Mackie Research") to act as financial advisor to the Company and the services of Hybrid Financial Limited ("Hybrid") to assist the ...

  • CNW Group4 months ago

    Canntab Engages Industry Leader Lorne Gertner as Consultant

    TORONTO, July 16, 2018 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) ("Canntab" or the "Company"), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that it has engaged Lorne Gertner, one of the world's foremost investors in the cannabis industry and one of its trailblazing pioneers, as a strategic consultant.  Mr. Gertner has significant experience on the boards of a number of publicly traded cannabis companies, including Hiku Brands Company, and has developed a global network of contacts in the cannabis industry along with a deep understanding of retail distribution, both of which Canntab hopes to leverage as it positions itself for expansion into international markets. Mr. Gertner is a serial entrepreneur with experience in start-ups, IPOs, fashion, retail, architecture, real estate, and finance.

  • Newsfile4 months ago

    InvestmentPitch Media Video Discusses Canntab Therapeutics LOI with FSD Pharma to Obtain License to Process and Sell Cannabis Based Products - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - July 11, 2018) - Canntab Therapeutics (CSE: PILL), a cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has entered into a non-binding letter of intent with FSD Pharma Inc. (CSE:HUGE). FSD Pharma, through its wholly-owned subsidiary FV Pharma, is a licensed producer under the Access to Cannabis for Medical Purposes Regulations.InvestmentPitch Media has produced a "video" which provides ...

  • CNW Group4 months ago

    Canntab announces collaboration and profit sharing agreement with FSD Pharma to produce and market oral dose delivery platforms

    TORONTO, July 9, 2018 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) ("Canntab"), a leader in the rapidly growing cannabis pill market, is pleased to announce that it has entered into a non-binding letter of intent (the "LOI") with FSD Pharma Inc. (CSE:HUGE) ("FSD Pharma"), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations. Under the terms of the LOI, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the "License"), and will provide Canntab with space at its 620,000 square foot facility (the "FSD Facility"), which is located just one hour east of Toronto in Cobourg, Ontario (the "Transaction"). FSD Pharma will provide Canntab with up to 10,000 square feet of space at the FSD Facility (the "Canntab Premises").

  • Canntab Announces Launch of Innovative Hemp Oil Capsules
    Newsfile5 months ago

    Canntab Announces Launch of Innovative Hemp Oil Capsules

    Toronto, Ontario--(Newsfile Corp. - June 20, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") is pleased to announce the Health Canada approval and launch of the first of its '420 Therapeutics' brand of Cannabis wellness products: Hemp Oil Gel Capsules. Made from purified organic hemp seed oil, the Hemp Oil Gel Capsules are an easy and convenient way to enjoy the health benefits of hemp oil.Each Hemp Oil Gel Capsule contains ...

  • Newsfile5 months ago

    Canntab Announces Director Resignation

    Toronto, Ontario--(Newsfile Corp. - June 14, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") announces that Sheldon Inwentash has resigned from the Company's Board of Directors to pursue other opportunities. Mr. Jeffrey Renwick, Chief Executive Officer of Canntab, stated, "I would like to thank Sheldon for his valuable contributions to the Company and, on behalf of the Board, I wish him every success in his future endeavours."About CanntabCanntab Therapeutics Limited is ...

  • Newsfile6 months ago

    Canntab Therapeutics Files 2 New Canadian Patent Applications Related to Pharmaceutical Cannabis

    Toronto, Ontario--(Newsfile Corp. - May 25, 2018) - Canntab Therapeutics Limited (CSE: PILL) (formerly Telferscot Resources Inc.) ("Canntab" or the "Company") is pleased to announce that it continues to expand its extensive intellectual property portfolio through the recent filing of 2 additional Canadian patent applications. Canntab's portfolio now includes 13 patent applications in Canada, the United States and internationally. These filings build on Canntab's growing intellectual property portfolio, which already included patent applications and ...